Back to Authors

Costantino, Félicie

0000-0002-1449-959X

Mayo Clinic

Inserm

Citations 1

Novel risk loci in LGI1-antibody encephalitis: genome-wide association study discovery and validation cohorts
Elliott, Katherine S. , Gilbert, Edmund , Harper, Andrew R. , Sempere, Vicente Peris, Pinto, Anne‐Laurie , Rayner, N. William, Mentzer, Alexander J. , Delanty, Norman, Picard, Géraldine , Titulaer, Maarten J. , Kuhlenbäeumer, Gregor, Mignot, Emmanuel , Cavelleri, Gianpiero L, Irani, Sarosh R. , Cavalleri, Gianpiero L. , Mentzer, Alexander J , Handel, Adam , Melzer, Nico , Lee, Soon-Tae , Leypoldt, Frank , Honnorat, Jérôme , Mignot, Emmanuel , Irani, Sarosh R , Cavalleri, Gianpiero L , Titulaer, Maarten J , Binks, Sophie , Muñiz‐Castrillo, Sergio , Araujo, Tânia Kawasaki de , Brown, Andrew , Chong, Amanda Yoon-Yee , Band, Gavin , Costantino, Félicie , Rogemond, Véronique , Handel, Adam E. , Lee, Soon‐Tae , Honnorat, Jérôme , Knight, Julian Charles

Brain | October 24, 2024 | Volume: 148 | Issue: 3 | Pages: 737-745

10.1093/brain/awae349 Get It

Abstract Encephalitis with antibodies to leucine-rich glioma-inactivated 1 (LGI1-Ab-E) is a common form of autoimmune encephalitis, presenting with seizures and neuropsychiatric changes, predominantly in older males. More than 90% of patients carry the human leukocyte antigen (HLA) class II allele, HLA-DRB1*07:01. However, this is also present in 25% of healthy controls. Therefore, we hypothesized the presence of additional genetic predispositions. In this genome-wide association study and meta-analysis, we studied a discovery cohort of 131 French LGI1-Ab-E and a validation cohort of 126 American, British and Irish LGI1-Ab-E patients, ancestry-matched to 2613 and 2538 European controls, respectively. Outside the known major HLA signal, we found two single nucleotide polymorphisms at genome-wide significance (P < 5 × 10−8), implicating PTPRD, a protein tyrosine phosphatase, and LINC00670, a non-protein coding RNA gene. Meta-analysis defined four additional non-HLA loci, including the protein coding COBL gene. Polygenic risk scores with and without HLA variants proposed a contribution of non-HLA loci. In silico network analyses suggested LGI1 and PTPRD-mediated interactions via the established receptors of LGI1, ADAM22 and ADAM23. Our results identify new genetic loci in LGI1-Ab-E. These findings present opportunities for mechanistic studies and offer potential markers of susceptibility, prognostics and therapeutic responses.